Insights

For more than a decade, the electronic Common Technical Document (eCTD) has been the global standard for electronic regulatory submissions in the life sciences industry. With the introduction of eCTD 4.0, regulatory submissions are evolving from a document‑centric model to a data‑driven, digitally enabled framework.

Unlike previous versions, eCTD 4.0 is built on structured XML and the HL7 RPS standard, enabling regulatory information to be managed, updated, and reused more efficiently across the product lifecycle. Key improvements include enhanced lifecycle management, reduced content duplication through document re‑use (UUIDs), metadata‑driven submissions, and improved navigation.

In Europe, the transition to eCTD 4.0 is already underway.
The European Medicines Agency (EMA) launched optional use of eCTD 4.0 for new Centrally Authorised Product (CAP) marketing authorisation applications on 22 December 2025, following several technical pilot phases. Mandatory use for CAPs is planned from 2027, with further roll‑out to other procedures to follow. During this transition period, eCTD 3.2.2 and eCTD 4.0 will coexist, making early preparation essential for applicants.

For pharmaceutical and life sciences companies, eCTD 4.0 is more than a technical upgrade. It represents a strategic opportunity to modernise regulatory operations, strengthen data governance, and align regulatory processes with broader digital transformation initiatives. As global health authorities continue to advance toward eCTD 4.0 adoption, starting the journey today is key. Organisations that act early will be better positioned to meet evolving expectations with efficiency, quality, and confidence.

RPN is ready to support the transition to eCTD 4.0 in the creation of regulatory sequences using eCTD version 4.0, providing the expertise and operational support needed to implement the new standard and prepare for future regulatory requirements.